351. Chierakul N. Intrapulmonary pharmacokinetics of ofloxacin in drug-
resistant tuberculosis / N/ Chierakul, D. Klomsawat, S. Chulavatnatol et al. // Int. J.
Tuberc. Lung. Dis. - 2001. - Vol. 5, № 3. - P. 278-282.
352. Chinnery P. Epidemiology and treatment of mitochondrial dysorders /
P Chinnery // Am. J. Med. Genet. (Semin. Med. Genet.). - 2001. - Vol. 106. - P.
94-101.
353. Chaulet P. Observed treatment of tuberculosis patient in ambulatory
conditions / P. Chaulet // Rev. Mai. Respir. - 1986. - № 3. - P. 65-66.
354. Clinical significance of variability of ventricular late potentials detected
before discharge in patients after myocardial infarction // Am. Heart J. - 2000. -
Vol. 139.- P . 134-141.
355. Coker R. Lessons from New York’s tuberculosis epidemic / R. Coker //
The Brit. Med. J. - 1998. - Vol. 317, P. 616-620.
356. Cripps Т. K. Prognostic value of reduced of heart rate variability after
myocardial infarction: clinical evolution of anew analysis methods / Т.К. Cripps,
M. Malik, T.O. Farell // Br. Heart. J. - 1991. - Vol. 65. - P. 14-19.
357. Crofton S.J. Guidelines for the management of drug-resistant
tuberculosis / S.J. Crofton, P. Chaulet, D. Maher et al. // World Health
Organization, 1998 .- 47 p.
358. Dandona P. Para-aminosalicylic acid-induced hypoglycaemia in a
patients with diabetic nephropathy / P. Dandona, E. Greenbury, A.G. Beckett //
Postgrand Med. J. - 1 9 8 0 . -Vol. 56 .- P . 135-136.
359. Darr M. Acid-base and electrolyte abnormalities due to capreomycin /
M. Darr, S. Hamburger, E. Ellerbeck // Sauthem Medical Journal. - 1982. - Vol.
75, № 5. - P 627-628.
360. Devoto F.M. Risk factors for hepatotoxicity induced by antituberculosis
drugs / F.M. Devoto, C. Gonzalez, R. Iannantuono et al. // Acta Physiol.
Pharmacol. Ther. Latinoam. - 1997. - Vol. 47, № 4. - P. 197-202/
395
